Analysis of Pfizer's financial performance, acquisitions, and future prospects, highlighting key challenges and opportunities ...

Pfizer, a multinational pharmaceutical and biotechnology corporation, is now a $159 billion (by market cap) healthcare giant.

Pfizer has a pill it's developing called danuglipron, which is in early-stage trials but has demonstrated that it's ...

During the COVID pandemic's height, for example, Pfizer was not only the co-developer of the widely distributed Comirnaty vaccine, it was also the entity behind the go-to drug therapy Paxlovid.

Unlike at the height of the pandemic, oral antiviral therapy Paxlovid is Pfizer's strongest COVID-19 product now instead of its Comirnaty vaccine. In the third quarter of 2024, Paxlovid raked in ...

Is it true that the higher the dividend yield, the riskier the dividend? Not always. Some companies with exceptionally high dividend yields can easily afford to keep the dividends flowing.

Fiera Capital Corp trimmed its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 2.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission ...

On Oct. 29, Pfizer PFE announced third-quarter results, beating estimates for earnings as well as sales. Revenues rose 32% on ...

Pfizer shares climbed in early trading. The drugmaker said it made a one-time delivery of a million Paxlovid treatment courses to the U.S. Strategic National Stockpile in the third quarter. Pfizer ...

Including the contribution from Seagen and excluding revenues from Comirnaty and Paxlovid, Pfizer (PFE) continues to expect full-year 2024 operational revenue growth of 9% to 11% compared to 2023 ...

Pfizer Inc ( (PFE) ) has realeased its Q3 earnings. Here is a breakdown of the information Pfizer Inc presented to its investors. Pfizer Inc., ...